Gritgen Therapeutics Co., Ltd.
Quick facts
Phase 3 pipeline
- GS1191-0445 injection
GS1191-0445 injection is a therapeutic agent that targets a specific molecular pathway.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Gritgen Therapeutics Co., Ltd. portfolio CI brief
- Gritgen Therapeutics Co., Ltd. pipeline updates RSS
Frequently asked questions about Gritgen Therapeutics Co., Ltd.
What is Gritgen Therapeutics Co., Ltd.'s pipeline?
Gritgen Therapeutics Co., Ltd. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include GS1191-0445 injection.
Related
- Sector hub: All tracked pharma companies